Tests a device for atrial fibrillation during heart surgery

Trial details

Who runs it

Pulse Biosciences, Inc.

Trial code

NCT06959121

Record updated

9 September 2026

Original description

The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.Read full original descriptionShow less

Pulse Biosciences' CellFX nsPFA Cardiac Surgery Clamp System for the Treatment of Atrial Fibrillation During Concomitant Cardiac Surgery

The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.

Inclusion: Subject must be between 18 and 85 years of age; Subject is willing and capable of providing Informed Consent to undergo study procedures which include the potential for surgical AF ablation, and completion of follow-up visits as specified in the clinical study protocol; Subject has history of documented paroxysmal atrial fibrillation (AF that is intermittent and terminates within ≤ 7 days of onset) or persistent/longstanding persistent atrial fibrillation (AF that is continuous and sustains for > 7 days and requires intervention) within one year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), Holter monitor or telemetry strip from the study hospital or an outside physician; Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery via sternotomy for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, Atrial Septal Defect (ASD)/Patent Foramen Ovale (PFO) or Coronary artery bypass procedures; Left ventricular ejection fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history); Subject has a life expectancy of at least 5 years; Subject currently lives within a reasonable commuting distance of the investigational site and plans to remain geographically stable through 12 month follow up.

Exclusion: Stand- alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery; Prior cardiac surgery including prior cardiac surgical ablation; Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation); Prior history of stroke within 6 months; Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment; A known drug and/or alcohol addiction; Subjects who have been treated with thoracic radiation; Subjects in current chemotherapy; Subjects on long-term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases); Solid organ or hematologic transplant, or currently being evaluated for an organ transplant; Use of any other investigational drug, therapy, or device within 30 days before enrollment or concurrent participation in another research study; Subject has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter-defibrillator (ICD), or Cardiac Resynchronization Therapy (CRT) or left atrial appendage (LAA) device; Subject has a prosthetic heart valve; Wolff-Parkinson-White syndrome or other Supra-Ventricular Arrhythmia, Atrioventricular (AV) nodal reentry; Documented history of persistent or long standing persistent atrial fibrillation longer than 10 years; Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or atrial septal defect repair/PFO and ascending aorta; Subjects that are on an AAD for ventricular arrhythmia; Class III or IV New York Heart Association (NYHA) heart failure symptoms; Need for emergent cardiac surgery (per sit-to-stand (STS) test definition); Current diagnosis of active systemic infection; Severe peripheral arterial occlusive disease defined as claudication with minimal exertion; Renal failure requiring dialysis or hepatic failure (significant liver dysfunction with markedly significant elevation of liver enzymes, such as cirrhosis with decompensation, portal hypertension, or a history of hepatic failure); Mental impairment or other conditions that may not allow the subject to understand the nature, significance, and scope of the study; Subject has a contraindication to anticoagulation (e.g., a bleeding or clotting disorder such as Idiopathic Thrombocytopenic Purpura (ITP)); Any diagnosed connective tissue disorder; Severe Chronic Obstructive Pulmonary Disease (COPD) per sit-to-stand (STS) test definition; Subject has history or known to have LAA clot; Left Atrial diameter ≥ 6cm; STS Predicted Risk of Mortality (STS PROM) of 10 or higher; Known carotid artery stenosis greater than 80%; Pregnancy or desire to get pregnant within 12 months of the study treatment; Preoperative need for an intra-aortic balloon pump or intravenous inotropes; Subjects with known hypertrophic obstructive cardiomyopathy; Subjects with known cold agglutinin; Body mass index > 45 kg/m2.

ClinicalTrials.gov NCT06959121